418 results about "Tetrahydropyran" patented technology

The present invention is directed to a method of making a ligand which can be used to form an ansa-metallocene. Further, the present invention is directed to a method of making the ansa-metallocene. In both methods the process steps employed to form the ligand are conducted in the presence of tetrahydrofuran, a substituted tetrahydrofuran, tetrahydropyran, a substituted tetrahydropyran or ethylene glycol dimethyl ether.

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

The present invention is one kind of 17-hydroxy C27 steroid compound and its synthesis and use. The synthesis process of the present invention is simple and suitable for industrial production in synthesizing pennogenin as well as dihydro pennogenin and OSW-1 aglycone analog.

The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic glutamate receptors subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and such compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

A polymeric compound of the invention includes at least one monomer unit selected from the following formulae (I), (II), (III) and (IV):(wherein R<1 >is a hydrogen atom or a methyl group, R<2 >and R<3 >are each a hydrogen atom, a hydroxyl group or a -COOR<4 >group, where R<4 >is, e.g., a t-butyl group or a 2-tetrahydropyranyl group; R<5 >and R<6 >are each a hydrogen atom, a hydroxyl group or an oxo group; R<7>, R<8 >and R<9 >are each a hydrogen atom or a methyl group; R<10 >and R<11 >are each a hydrocarbon group having 1 to 8 carbon atoms; R<12>, R<13 >and R<14 >are each a hydrogen atom, a hydroxyl group or a methyl group, where if all of R<12 >to R<14 >are each a hydrogen atom or a hydroxyl group, R<10 >and R<11 >are not coincidentally methyl groups) [wherein, when the compound includes, for example, a monomer unit of Formula (III), the compound further includes at least one monomer unit selected from among, for example, a monomer unit represented by the following Formula (V):(wherein R<15 >and R<16 >are each a hydrogen atom, a hydroxyl group or a carboxyl group; R<17 >is a hydroxyl group, an oxo group or a carboxyl group; and R<1 >has the same meaning as defined above)]. This polymeric compound has high etching resistance, as well as satisfactory transparency, alkali-solubility and adhesion, and is therefore useful as a photoresist resin.

The invention discloses a synthetic method to prepare polyurethane elastic body with hydroxyl-ended oligomer polyol as raw material, which is characterized by the following: reacting hydroxy-terminated liquid rubber or poly-tetrahydropyran ether alcohol with polyisocyanates; getting end isocyanate group pie polymer in fixing reacting time, temperature; giving in A component; compositing chain-extending agent, flux, antiager with gallant; getting curative; giving in B component; hardening A component and B component under indoor temperature proportional mixing; getting high-performance multipurpose polyurethane elastic body; The stretching intensity is: 10.0-47.0Mpa, splitting extensibility>300%, 300% load at certain intensity: 5.0-35.0Mpa.

A liquid crystal compound selected from a group of compounds represented by formula (a):

wherein Ra and Rb are each independently alkyl having 1 to 10 carbons, alkoxy having 1 to 9 carbons, alkoxyalkyl having 2 to 9 carbons, alkenyl having 2 to 10 carbons, alkenyloxy having 2 to 9 carbons, fluoroalkyl having 1 to 10 carbons or fluoroalkoxy having 1 to 9 carbons; ring A¹, ring A² and ring A³ are each independently trans-1,4-cyclohexylene, trans-1,3-dioxane-2,5-diyl, trans-tetrahydropyran-2,5-diyl, 1,4-phenylene, 2-fluoro-1,4-phenylene, 2,3-difluoro-1,4-phenylene, 2,5-difluoro-1,4-phenylene, 2,6-difluoro-1,4-phenylene, pyridine-2,5-diyl, 6-fluoropyridine-2,5-diyl or pyridazine-2,5-diyl; Z¹, Z² and Z³ are each independently a single bond, —(CH₂)₂—, —CH═CH—, —C≡C—, —CH₂O, —OCH₂—, —COO—, —OCO—, —OCF₂—, —CF₂O—, —CH₂CH₂OCF₂— or —CF₂OCH₂CH₂—; l, m and n are each independently 0, 1 or 2, provided that l+m+n is 0, 1, 2 or 3; one of X¹ and X² is fluorine, and the other is chlorine; Q is

and atoms comprising the compound each may be an isotope thereof.

This invention refers to 17alpha ,22 - dihydroxy Furan Steride compounds and its application. The compound' s structure formula is drawing in right graph, wherein the R1, R2 and R3 = H, C1-10 direct chain, cyclane group or alkenyl , triethylsilyl, dimethyl- tert-butylsilyl-biphenyl-tert-butylsilyl, methoxymethyl or tetrahydropyranyl. R4 = H see right formula a, b, C1-10 direct chain, cyclane group, alkenyl or alkynyl , R5 = C1-10 direct chain or cyclane group, R6 = H, C1-10 direct chain or cyclane group or alkenyl, triethylsilyl, dimethyl- tert-butylsilyl, biphenyl-tert-butylsilyl, methoxymethyl, tetrahydropyranyl. The start materials is diosgenin, which is easy available and cheap. Through F-cyclic degrading, the degradation product' s structure is converted into 17alpha,22 - dihydroxy furan steride compound. The compound again with F-cyclic restructure becomes the sapogenin, which is medicinal value. The process thereof is simple, adapted for industrialized production. It's glycoside of medicinal herbs Chonglou (Paris petiolata bak) sapogenin as one active ingredient, whose synthesis is provided herewith is effectively.

The invention discloses a Bose factor polypeptide anti-wrinkle eye cream and a preparation method thereof. The eye cream provides a conditioner with main active ingredients, and the conditioner comprises tocopheryl acetate, hexapeptide-9, palmitoyl pentapeptide-4, tripeptide-1, palmitoyl palmitoyl tripeptide-5, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, hydroxypropyl tetrahydropyrantriol (Bose factor), carnosine, glycosphingolipid, illicium verum callus culture filtrate and rosa damascena flower oil. The eye cream can effectively promote the generation of eye skin collagen, increase theelasticity and compactness of the skin, prevent wrinkles from deepening and repair the damaged barrier of the eye skin, and has the effects of wrinkle resistance, whitening and oxidation resistance.

The invention relates to a method for producing 2- and 2,5-substituted derivatives of 4-(trifluoromethyl)-phenol and 4-(2-trifluoromethyl)-phenyl)-2-tetrahydropyranyl) ether and to novel derivatives. Said method is characterised in that a compound of formula (2) 4-(trifluoromethylphenyl)-2-(tetrahydropyranyl) ether is reacted with an electrophile E-X or a combination of electrophiles E-X and E-Y in the presence of a base, X and Y having the meanings given in the description.

The invention relates to a method for preparing an intermediate of axitinib and application of the intermediate in preparation of axitinib. The preparation method for the intermediate of axitinib 3-iodine-6-nitro-1-(teralin-2H-pyran-2-base)-1H-indazole comprises the following steps that 6-nitroindazole and 3,4-dihydro-2H-pyran react under the action of catalyst so as to protect perssad tetralin-2H-pyran-2-base at N-H site, and the key intermediate with high yield is obtained through iodination at site 3. The application of the intermediate in preparation of axitinib is as follows: Heck coupled reaction is carried out on the intermediate and 2-vinyl pyridine, then nitro reduction and diazo-reaction for iodination are sequentially carried out, finally, the axitinib is obtained after docking of 2-sulfydryl-N-methyl benzamide and deprotection. The related main initial raw materials are easy to purchase in markets, and the method has high yield and high molecule economic efficiency, is efficient and environment-friendly, and is suitable for industrial mass production.

The invention discloses a synthetic method of hydroxypropyl tetrahydropyrantriol, belonging to the technical field of fine chemicals. Xylose is used as a raw material and is subjected to a two-step reaction to prepare hydroxypropyl tetrahydropyrantriol. The synthetic method is simple in preparation process, preparation yield is high, reagents are cheap and easy to obtain, and good industrial prospects are obtained.

The present invention relates to compound with 6-aryl-3-substituted methylene-pyrone structure, derivative with 6-aryl-3-methyl-4-acryloxy tetrahydro pyrone skeleton, and their preparation process and use. Pharmacological activity test shows that the compound possesses acetylcholinesterase inhibiting activity and is expected to be used as medicine for senile dementia. The compound also shows relatively high activity of inhibiting tumor cells of prostate cancer, oral epithelium cancer, lung cancer and cervical cancer and thus is expected to be used as antitumor medicine.

A liquid crystal composition exhibits a positive dielectric anisotropy and sufficiently low viscosity without decreasing or increasing refractive index anisotropy or nematic phase-isotropic liquid phase transition temperature, and does not cause display failures. The liquid crystal composition contains one or more compounds selected from compounds represented by general formula (LC0) and one or more compounds selected from a group of compounds represented by general formula (LC1) to general formula (LC5), in which the liquid crystal composition contains one or more compounds in which at least one of A⁰¹, A⁰², and A¹¹ to A⁴² in general formulae (LC0) to (LC4) represents a tetrahydropyran-2,5-diyl group.

Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.

The present invention relates to a method for the production of 2-substituted 4-hydroxy-4-methyltetrahydropyrans from the acid-catalyzed reaction of 3-methylbut-3-ene-1-ol with an aldehyde, a stable odoriferous quality being achieved and avoiding off-odors that interfere with the odor sensation.